Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PureTech Health announced a successful funding round totaling $106.5 million led by new investors AXA IM Alts and The AMR Action Fund. This financing will enable the pivotal Phase 3 study of VE303, targeting recurrent C. difficile infections, set to commence by the third quarter of 2023. Additionally, it will support a Phase 2 study of VE202 for ulcerative colitis, expected to begin in the second quarter of 2023. The investment syndicate includes notable entities such as the Bill & Melinda Gates Foundation and Pfizer. Vedanta Biosciences, a PureTech-founded entity, aims to pioneer a new category of oral therapies using defined bacterial consortia, enhancing treatment efficacy and safety. This funding marks a significant step toward advancing microbiome therapeutics.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced the publication of Phase 2 study results for VE303 in the Journal of the American Medical Association. This study demonstrated VE303's effectiveness in preventing recurrent Clostridioides difficile infection (CDI). The results indicate a significant reduction in CDI recurrence rates at 24 weeks and improved gut microbiome diversity. Additionally, VE303 showed a relationship between bacterial colonization and clinical response. The data were also presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). VE303 utilizes a defined bacterial consortium approach, offering potential advantages over traditional fecal donor methods, including consistency and scalability.